News|Articles|December 27, 2024

2024 Brings Change, New Hope for Nonhormonal Management of Menopause

Neurokinin-3 receptor antagonists such as elinzanetant and fezolinetant provide non-hormonal options for managing hot flashes linked to menopause.

While vasomotor symptoms (VMS) have significant adverse impacts on the quality of life in menopausal women, elinzanetant and fezolinetant have emerged as promising non-hormonal treatments to alleviate symptoms, marking significant advances in menopausal health in 2024.